New research has uncovered how lipid-rich fluid in the abdomen, known as ascites, plays a central role in weakening the body's immune response in advanced ovarian cancer. The findings offer new ...

Led by Ludwig Princeton's Lydia Lynch and reported in the current issue of Science Immunology, the study details how ascites fluid-produced in large quantities as ovarian cancer spreads from the ...

Rae Hyndman was diagnosed with advanced ovarian cancer in November 2023, after noticing bloating in her stomach.

The studies also pointed to the polar lipid PC (36:1) as a contributor to NK cell dysfunction in ovarian cancer, with data suggesting “… that uptake of PC (36:1), and likely other certain ...

In 2023, the Rivkin Center partnered with the Andy Hill Cancer Research Endowment (CARE) Fund to fund $1 million in grants for research institutions in Washington state to unlock answers in ovarian ...

Recent advances in the understanding of advanced ovarian cancer (aOC) genomics have begun to challenge the treatment paradigm for this difficult disease. Although several genomic aberrations have ...

From the perspective of potential targets, ovarian cancer is the most interesting neoplasm, with numerous molecules potentially usable in ADC-based therapies, including the folate receptor (FR ...

Session ID: 2025-07-30:80e634c33f912f73becf5602 Player Element ID: vjs_video_3 ...

Rinatabart sesutecan (Rina-S) is an antibody-drug conjugate that targets folate receptor-alpha (FRα) and delivers a TOP1 inhibitor directly to cancer cells, according to a press release, which went on ...

Key Takeaways Zentalis Pharmaceuticals progresses with azenosertib in the DENALI trial for Cyclin E1-positive platinum-resistant ovarian cancer, aiming for FDA approval by 2026. Part 2a of the trial ...

Patients with high-risk advanced ovarian cancer obtained a marginal survival benefit with the addition of bevacizumab (Avastin) to first-line chemotherapy, while patients without high risk did not ...